Real-World Skin Clearance and Quality of Life with risankizumab in Patients with Psoriasis with Moderate Skin Involvement and Those Eligible for Systemic Therapy Per International Psoriasis Council Classification

By afschroeder • July 2, 2025

Strober B, Patel M, Kaldas MI, St John G, Photowala H, Sima AP, Eckmann T, Beeghly A, Armstrong A. Real-World Skin Clearance and Quality of Life with risankizumab in Patients with Psoriasis with Moderate Skin Involvement and Those Eligible for Systemic Therapy Per International Psoriasis Council Classification. Dermatol Ther (Heidelb). 2025 Jul 2. doi: 10.1007/s13555-025-01474-3. Epub ahead of print. PMID: 40593269.

Tags: CorEvitas Psoriasis Registry, Dermatology, International Psoriasis Council disease reclassification, National Psoriasis Foundation treat-to-target goals, patient-reported outcomes, psoriasis, Publications, real-world, risankizumab, Skin clearance, Systemic-eligible

Chronic Urticaria Is Independently Associated with Atherosclerotic Cardiovascular Disease: A National Cohort Study of the MarketScan Databases

Cortes JA, Nong Y, Smart K, Aflatooni S, Palma G, Johnsen N, Ure A, Armstrong AW. Chronic Urticaria Is Independently Associated with Atherosclerotic Cardiovascular Disease:[...]

Treatment Patterns and Economic Burden in Moderate to Severe Chronic Hand Eczema in the USA: A Real-World Retrospective Claims Analysis

Armstrong AW, Burne R, Bin Sawad A, Lemyre A, Gauthier-Loiselle M, Guerin A, Vinson T, Milovac B, Balu S. Treatment Patterns and Economic Burden in[...]

DNA methylation profiles at hospital admission are associated with subsequent severe COVID-19 outcomes

Hsu FM, Pickering H, Bosinger SE, Eckalbar W, Maecker HT, Kim-Schulze S, Ozonoff A, Diray-Arce J, Schaenman JM, Reed EF, Pellegrini M. DNA methylation profiles[...]